NCR Online Journal

Acute Kidney Injury treatment market to derive enormous growth from the expected launch of emerging therapies in the forecast period (2021-30)

 Breaking News
  • No posts were found

Acute Kidney Injury treatment market to derive enormous growth from the expected launch of emerging therapies in the forecast period (2021-30)

September 02
22:39 2021
Acute Kidney Injury treatment market to derive enormous growth from the expected launch of emerging therapies in the forecast period (2021-30)
Acute Kidney Injury Market
The current Acute Kidney Injury therapeutic market size in the United States is mainly based on Renal Replacement Therapy (RRT) and off-label drugs.

DelveInsight’s Acute Kidney Injury (AKI) market report thoroughly explains the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), And Japan). The report also proffers an analysis of the current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs.

Some of the Important Findings from the Acute Kidney Injury Market Report

  • As per DelveInsight’s Acute Kidney Injury epidemiology insights, the total incident population was estimated to be over 10 million in the 7MM in 2020.

  • Among the 7MM, the estimates show a higher incident population of Acute Kidney Injury in the United States with 895,078 cases in 2020.

  • Several players such as Angion Biomedica, Vifor Pharma, Quark Pharmaceutical, Novartis, Astellas Pharma, MediBeacon, PharmingTechnologies, AM Pharma, Alloksys, Exponential Biotherapies, and others are working robustly to bring the emerging therapies in the market for Acute Kidney Injury patients. 

  • Key pipeline therapies that are anticipated to launch and join the Acute Kidney Injury market in the upcoming years include ANG-3777, QPI-1002, ASP1128, Lumitrace, Ruconest (Conestat alfa), bRESCAP, EA-230, recAP, and several others.

  • AM Pharma’s recAP is a recombinant alkaline phosphatase made up of two naturally occurring human isoforms of the AP enzyme. The US Food and Drug Administration has given Fast Track designation to recAP. Currently, it is in Phase III Acute Kidney Injury clinical trials.

  • QPI-1002 (teprasiran) is a synthetic double-stranded RNA oligonucleotide being developed by Quark Pharmaceutical and currently, it is in Phase III of clinical development for Acute Kidney Injury treatment. QPI-1002 has received Fast Track designation from the US FDA and Orphan Drug designation from the US FDA and EMA for delayed graft function.

  • Exponential Biotherapies is developing EA-230, an intravenously administered chemically synthesized linear peptide that is a derivative of human pregnancy hormone that is used for immunomodulation.

Have queries? Request for sample @ Acute Kidney Injury Market

The Acute Kidney Injury (AKI) market report also covers current treatment practises, emerging drugs, and market share of individual therapies, as well as the current and projected 7MM Acute Kidney Injury (AKI) market size from 2018 to 2030. 

Acute Kidney Injury: Overview

Acute Kidney Injury (AKI), also known as Acute Renal Failure (ARF), is characterized by azotemia that worsens over several hours or days and can be accompanied by oliguria. ARF is commonly defined as a sudden decline in renal function, clinically manifested as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over hours to weeks. The disease causes a sudden loss of kidney function, resulting in waste product retention, electrolyte disturbances, and volume status changes.

Acute Kidney Injury Epidemiology Segmentation

The Acute Kidney Injury report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Acute Kidney Injury Total Incident Patient Population

  • Acute Kidney Injury Discharge Diagnosed Cases 

  • Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases

  • Risk Factor Associated Acute Kidney Injury Cases

  • Renal Transplantation Associated Delayed Graft Function Cases

Acute Kidney Injury Treatment Landscape

There are currently no approved targeted pharmacotherapies for the treatment of Acute Kidney Injury. Currently, the Acute Kidney Injury therapeutic market size in the United States is primarily accounted for by the use of Renal Replacement Therapy (RRT) and off-label drugs, such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Acute Kidney Injury Market

  • The Acute Kidney Injury market size was found to be USD 5,436 million in the 7MM in 2020. 

  • Among the 7MM, the United States accounted for the maximum Acute Kidney Injury market share in 2020.

  • The Acute Kidney injury market size is anticipated to increase due to the launch of upcoming therapies such as ANG-3777, QPI-1002, ASP1128, along with others.

Acute Kidney Injury Pipeline Therapies and Key Companies 

  • ANG-3777: Angion Biomedica/ Vifor Pharma

  • QPI-1002: Quark Pharmaceutical/Novartis

  • ASP1128: Astellas Pharma

  • Lumitrace: MediBeacon

  • Ruconest (Conestat alfa): Pharming Technologies 

  • bRESCAP: Alloksys

  • EA-230: Exponential Biotherapies

  • recAP: AM Pharma

Learn more about the emerging therapies and companies @ Global Acute Kidney Injury Treatment Market

Acute Kidney Injury Market Drivers

  • Robust Pipeline Activity

  • Increased incidence of hospitalization

  • Reimbursement policies

Acute Kidney Injury Market Barriers

  • Disease burden

  • Morbidity/ mortality

  • Disease management & treatment

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Acute Kidney Injury Key Companies: Angion Biomedica, Vifor Pharma, Quark Pharmaceutical, Novartis, Astellas Pharma, MediBeacon, PharmingTechnologies, AM Pharma, Alloksys, Exponential Biotherapies, among others. 

Acute Kidney Injury Key Pipeline Therapies: ANG-3777, QPI-1002, ASP1128, Lumitrace, Ruconest (Conestat alfa), bRESCAP, EA-230, recAP, and others.

Acute Kidney Injury Segmentation: By Geography, By Acute Kidney Injury therapies

Analysis: Comparative and conjoint analysis of Acute Kidney Injury emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Key Insights

2.

Acute Kidney Injury Market (AKI): Overview at a Glance

3.

Acute Kidney Injury (AKI): Disease Background and Overview

4.

Acute Kidney Injury Epidemiology and Patient Population

5.

Acute Kidney Injury United States Epidemiology

6.

Acute Kidney Injury EU5 Epidemiology

7.

Acute Kidney Injury Japan Epidemiology

8.

Acute Kidney Injury Treatment and Prevention

9.

Acute Kidney Injury Unmet Needs

10.

Acute Kidney Injury Emerging Therapies

11.

Acute Kidney Injury: 7 Major Market Analysis

12.

Acute Kidney Injury United States Market Outlook

13.

Acute Kidney Injury EU-5 Countries: Market Outlook

14.

Acute Kidney Injury Japan: Market Outlook

15.

Trends in the Cost of Therapies in Acute Kidney Injury

16.

Acute Kidney Injury Market Drivers

17.

Acute Kidney Injury Market Barriers

18.

DelveInsight Capabilities

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Acute Pancreatitis Market

Get a comprehensive analysis of Acute Pancreatitis pipeline therapies and key companies such as CalciMedica, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles